Palvella Therapeutics, Inc. (PVLA) Equity Average (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Equity Average for 11 consecutive years, with -$84.1 million as the latest value for Q3 2024.
- On a quarterly basis, Equity Average fell 336.92% to -$84.1 million in Q3 2024 year-over-year; TTM through Sep 2024 was -$84.1 million, a 336.92% decrease, with the full-year FY2023 number at -$84.1 million, down 291.1% from a year prior.
- Equity Average was -$84.1 million for Q3 2024 at Palvella Therapeutics, down from -$78.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $180.9 million in Q3 2022 to a low of -$84.1 million in Q3 2024.
- A 5-year average of $27.3 million and a median of $42.5 million in 2021 define the central range for Equity Average.
- Peak YoY movement for Equity Average: skyrocketed 259.79% in 2022, then plummeted 381.83% in 2024.
- Palvella Therapeutics' Equity Average stood at $37.4 million in 2020, then surged by 40.0% to $52.3 million in 2021, then skyrocketed by 113.86% to $111.9 million in 2022, then crashed by 119.66% to -$22.0 million in 2023, then plummeted by 282.58% to -$84.1 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Equity Average are -$84.1 million (Q3 2024), -$78.9 million (Q2 2024), and -$75.7 million (Q1 2024).